Immunocore (IMCR) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunocore (IMCR) has outperformed Mesoblast (MESO) over the past year, losing 14.1% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -22.6% for IMCR. Mesoblast is the larger company by market cap ($1.74 billion vs $1.50 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | MESO |
|---|---|---|
| Share price | $29.17 | $13.43 |
| Market cap | $1.50B | $1.74B |
| 1-day change | -0.82% | -3.70% |
| YTD return | -15.27% | -22.73% |
| 1-year return | -14.06% | -22.94% |
| 5-year return | -22.61% | +22.71% |
| Forward P/E | — | 29.51 |
| EPS (TTM) | $-0.36 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.72 | $21.50 |
| 52-week low | $27.56 | $13.05 |
| Distance from 52-week high | -28.36% | -37.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +115.05% | +175.61% |
| Average volume | 447.09K | 232.53K |
| Shares outstanding | 51.50M | 129.85M |
| Employees | 524 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
IMCR vs MESO FAQ
Which is bigger, Immunocore or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.74B compared with $1.50B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or MESO?
IMCR returned -14.06% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.